Second People's Hospital of Hunan
6
2
2
1
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 6 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 1 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (6)
Clinical Safety and Efficacy of Flow-diverter in the Treatment of Intracranial Aneurysms
Role: collaborator
Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study)
Role: collaborator
Intrathecal Pemetrexed for SCLC Patients With Refractory Brain Metastases or Leptomeninges Metastatic
Role: collaborator
Urine-DNA Biomarkers in Detecting Bladder Cancer
Role: collaborator
Different Acupoints Compatibility Difference of the Effect of Treatment of the Diabetic Gastroparesis
Role: collaborator
Different Acupoints Compatibility Difference of the Effect of Treatment of the Primary Insomnia
Role: collaborator
All 6 trials loaded